Computationally guided high-throughput design of self-assembling drug nanoparticles
Source abstract
Abstract
Nanoformulations of therapeutic drugs are transforming our ability to effectively deliver and treat a myriad of conditions. Often, however, they are complex to produce and exhibit low drug loading, except for nanoparticles formed via co-assembly of drugs and small molecular dyes, which display drug-loading capacities of up to 95%. There is currently no understanding of which of the millions of small-molecule combinations can result in the formation of these nanoparticles. Here we report the integration of machine learning with high-throughput experimentation to enable the rapid and large-scale identification of such nanoformulations. We identified 100 self-assembling drug nanoparticles from 2.1 million pairings, each including one of 788 candidate drugs and one of 2,686 approved excipients. We further characterized two nanoparticles, sorafenib-glycyrrhizin and terbinafine-taurocholic acid both ex vivo and in vivo. We anticipate that our platform can accelerate the development of safer and more efficacious nanoformulations with high drug-loading capacities for a wide range of therapeutics.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Computational Drug Discovery Methods · Nanoparticles: synthesis and applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (48)
Show source-provided references
1. Hopkins, A. L., Keserü, G. M., Leeson, P. D., Rees, D. C. & Reynolds, C. H. The role of ligand efficiency metrics in drug discovery. Nat. Rev. Drug Discov. 13, 105–121 (2014).10.1038/nrd4163 ↗
2. Irwin, J. J. et al. An aggregation advisor for ligand discovery. J. Med. Chem. 58, 7076–7087 (2015).10.1021/acs.jmedchem.5b01105 ↗
3. Reker, D., Bernardes, G. J. L. & Rodrigues, T. Computational advances in combating colloidal aggregation in drug discovery. Nat. Chem. 11, 402–418 (2019).10.1038/s41557-019-0234-9 ↗
4. Owen, S. C., Doak, A. K., Wassam, P., Shoichet, M. S. & Shoichet, B. K. Colloidal aggregation affects the efficacy of anticancer drugs in cell culture. ACS Chem. Biol. 7, 1429–1435 (2012).10.1021/cb300189b ↗
5. Kipp, J. E. The role of solid nanoparticle technology in the parenteral delivery of poorly water-soluble drugs. Int. J. Pharm. 284, 109–122 (2004).10.1016/j.ijpharm.2004.07.019 ↗
6. Mcdonald, T. O. et al. Antiretroviral solid drug nanoparticles with enhanced oral bioavailability: production, characterization, and in vitro-in vivo correlation. Adv. Healthc. Mater. 3, 400–411 (2014).10.1002/adhm.201300280 ↗
7. Govender, T., Stolnik, S., Garnett, M. C., Illum, L. & Davis, S. S. PLGA nanoparticles prepared by nanoprecipitation: drug loading and release studies of a water soluble drug. J. Control. Release 57, 171–185 (1999).10.1016/S0168-3659(98)00116-3 ↗
8. Westesen, K., Bunjes, H. & Koch, M. H. Physicochemical characterization of lipid nanoparticles and evaluation of their drug loading capacity and sustained release potential. J. Control. Release 48, 223–236 (1997).10.1016/S0168-3659(97)00046-1 ↗
9. Reker, D. et al. ‘Inactive’ ingredients in oral medications. Sci. Transl. Med. 11, eaau6753 (2019).10.1126/scitranslmed.aau6753 ↗
10. McLaughlin, C. K. et al. Stable colloidal drug aggregates catch and release active enzymes. ACS Chem. Biol. 11, 992–1000 (2016).10.1021/acschembio.5b00806 ↗
11. Shamay, Y. et al. Quantitative self-assembly prediction yields targeted nanomedicines. Nat. Mater. 17, 361–368 (2018).10.1038/s41563-017-0007-z ↗
12. Inactive Ingredient Search for Approved Drug Products (FDA, 2016); https://www.accessdata.fda.gov/scripts/cder/iig/
13. Feng, B. Y., Shelat, A., Dorman, T. N., Guy, R. K. & Shoichet, B. K. High-throughput assays for promiscuous inhibitors. Nat. Chem. Biol. 1, 146–148 (2005).10.1038/nchembio718 ↗
14. SCOGS (Select Committee on GRAS Substances) (FDA, 2016); https://www.accessdata.fda.gov/scripts/fdcc/?set=SCOGS
15. Wishart, D. S. et al. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 46, D1074–D1082 (2018).10.1093/nar/gkx1037 ↗
16. Reker, D. et al. Machine learning uncovers food- and excipient-drug interactions. Cell Rep. 30, 3710–3716.e4 (2020).10.1016/j.celrep.2020.02.094 ↗
17. Reker, D., Schneider, P. & Schneider, G. Multi-objective active machine learning rapidly improves structure-activity models and reveals new protein-protein interaction inhibitors. Chem. Sci. 7, 3919–3927 (2016).10.1039/C5SC04272K ↗
18. Gregori-Puigjane, E. & Mestres, J. A ligand-based approach to mining the chemogenomic space of drugs. Comb. Chem. High T. Scr. 11, 669–676 (2008).
19. Wildman, S. A. & Crippen, G. M. Prediction of physicochemical parameters by atomic contributions. J. Chem. Inf. Comp. Sci. 39, 868–873 (1999).10.1021/ci990307l ↗
20. Chuang, K. V. & Keiser, M. J. Adversarial controls for scientific machine learning. ACS Chem. Biol. 13, 2819–2821 (2018).10.1021/acschembio.8b00881 ↗
21. Test no. 318: dispersion stability of nanomaterials in simulated environmental media. OECD Guidelines for the Testing of Chemicals, Section 3 https://doi.org/10.1787/9789264284142-en (2017).10.1787/9789264284142-en ↗
22. Lipner, S. R. & Scher, R. K. Onychomycosis: treatment and prevention of recurrence. J. Am. Acad. Dermatol. 80, 853–867 (2019).10.1016/j.jaad.2018.05.1260 ↗
23. McClellan, K. J., Wiseman, L. R. & Markham, A. Terbinafine. Drugs 58, 179–202 (1999).10.2165/00003495-199958010-00018 ↗
24. Matteucci, M. E., Hotze, M. A., Johnston, K. P. & Williams, R. O. Drug nanoparticles by antisolvent precipitation: mixing energy versus surfactant stabilization. Langmuir 22, 8951–8959 (2006).10.1021/la061122t ↗
25. Ganesh, A. N. et al. Colloidal drug aggregate stability in high serum conditions and pharmacokinetic consequence. ACS Chem. Biol. 14, 751–757 (2019).10.1021/acschembio.9b00032 ↗
26. Jayatilake, J. A. M. S., Tilakaratne, W. M. & Panagoda, G. J. Candidal onychomycosis: a mini-review. Mycopathologia 168, 165–173 (2009).10.1007/s11046-009-9212-x ↗
27. Cabral, H. et al. Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size. Nat. Nanotechnol. 6, 815–823 (2011).10.1038/nnano.2011.166 ↗
28. Wong, C. et al. Multistage nanoparticle delivery system for deep penetration into tumor tissue. Proc. Natl Acad. Sci. USA 108, 2426–2431 (2011).10.1073/pnas.1018382108 ↗
29. Pavlović, N. et al. Bile acids and their derivatives as potential modifiers of drug release and pharmacokinetic profiles. Front. Pharmacol. 9, 1283 (2018).10.3389/fphar.2018.01283 ↗
30. Villanueva, A. Hepatocellular carcinoma. N. Engl. J. Med. 380, 1450–1462 (2019).10.1056/NEJMra1713263 ↗
31. El-Serag, H. B. & Mason, A. C. Rising incidence of hepatocellular carcinoma in the United States. N. Engl. J. Med. 340, 745–750 (1999).10.1056/NEJM199903113401001 ↗
32. Isbrucker, R. A. A. & Burdock, G. A. A. Risk and safety assessment on the consumption of Licorice root (Glycyrrhiza sp.), its extract and powder as a food ingredient, with emphasis on the pharmacology and toxicology of glycyrrhizin. Regul. Toxicol. Pharm. 46, 167–192 (2006).10.1016/j.yrtph.2006.06.002 ↗
33. Basso, U., Brunello, A., Bertuzzi, A. & Santoro, A. Sorafenib is active on lung metastases from synovial sarcoma. Ann. Oncol. 20, 386–387 (2009).10.1093/annonc/mdn685 ↗
34. Chaparro, M., González Moreno, L., Trapero-Marugán, M., Medina, J. & Moreno-Otero, R. Review article: pharmacological therapy for hepatocellular carcinoma with sorafenib and other oral agents. Aliment. Pharm. Ther. 28, 1269–1277 (2008).10.1111/j.1365-2036.2008.03857.x ↗
35. Zhong, J. et al. Meloxicam combined with sorafenib synergistically inhibits tumor growth of human hepatocellular carcinoma cells via ER stress-related apoptosis. Oncol. Rep. 34, 2142–2150 (2015).10.3892/or.2015.4181 ↗
36. Auffan, M. et al. Towards a definition of inorganic nanoparticles from an environmental, health and safety perspective. Nat. Nanotechnol. https://doi.org/10.1038/nnano.2009.242 (2009).10.1038/nnano.2009.242 ↗
37. Lin, A. et al. Glycyrrhizin surface-modified chitosan nanoparticles for hepatocyte-targeted delivery. Int. J. Pharm. 359, 247–253 (2008).10.1016/j.ijpharm.2008.03.039 ↗
38. Tward, A. D. et al. Distinct pathways of genomic progression to benign and malignant tumors of the liver. Proc. Natl Acad. Sci. USA 104, 14771–14776 (2007).10.1073/pnas.0706578104 ↗
39. Bogorad, R. L. et al. Nanoparticle-formulated siRNA targeting integrins inhibits hepatocellular carcinoma progression in mice. Nat. Commun. 5, 3869 (2014).10.1038/ncomms4869 ↗
40. Lee, J. et al. Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell 9, 391–403 (2006).10.1016/j.ccr.2006.03.030 ↗
41. Sharpless, N. E. & DePinho, R. A. The mighty mouse: genetically engineered mouse models in cancer drug development. Nat. Rev. Drug Discov. 5, 741–754 (2006).10.1038/nrd2110 ↗
42. Waidely, E., Al-Yuobi, A. R. O., Bashammakh, A. S., El-Shahawi, M. S. & Leblanc, R. M. Serum protein biomarkers relevant to hepatocellular carcinoma and their detection. Analyst 141, 36–44 (2016).10.1039/C5AN01884F ↗
43. Lee, C. H. et al. Protective mechanism of glycyrrhizin on acute liver injury induced by carbon tetrachloride in mice. Biol. Pharm. Bull. 30, 1898–1904 (2007).10.1248/bpb.30.1898 ↗
44. Gelderblom, H., Verweij, J., Nooter, K., Sparreboom, A. & Cremophor, E. L. The drawbacks and advantages of vehicle selection for drug formulation. Eur. J. Cancer 37, 1590–1598 (2001).10.1016/S0959-8049(01)00171-X ↗
45. Singh, A., Iyer, A. K. & Amiji, M. M. in Handbook of Nanobiomedical Research (ed. Torchilin, V.) 199–233 (World Scientific Publishing Company, 2014); https://doi.org/10.1142/9789814520652_000610.1142/9789814520652_0006 ↗
46. Pohjala, L., Tammela, P., Pohjala, L. & Tammela, P. Aggregating behavior of phenolic compounds—a source of false bioassay results? Molecules 17, 10774–10790 (2012).10.3390/molecules170910774 ↗
47. Traverso, G. & Langer, R. Perspective: special delivery for the gut. Nature 519, S19 (2015).10.1038/519S19a ↗
48. Cheng, C. J. & Saltzman, W. M. Nanomedicine: downsizing tumour therapeutics. Nat. Nanotechnol. 7, 346–347 (2012).10.1038/nnano.2012.89 ↗